Preclinical data from tests of an experimental vaccine for solid tumours have shown complete tumour regression of transplanted human tumours in mice, according to the vaccine’s developer BioNTech SE. The RNA vaccine was designed to drive the expansion of an autologous CAR T cell therapy in vivo, thereby enabling the cell therapy to infiltrate solid tumours. Results of the study were published in Science on 2 January.
